



GeneCapture Awarded \$2.5 Million Contract to Provide Rapid Identification Solution for 'Pathogen X' Threats from Defense Threat Reduction Agency.

March 15, 2024

Huntsville, Alabama: GeneCapture, a Huntsville, Alabama company developing a one hour rapid diagnostic and follow-on antibiotic susceptibility platform for on-site management of infectious pathogens, announces a contract award of \$2.5 Million from the U.S. Department of Defense, Defense Threat Reduction Agency to continue the development of rapid pathogen detection in austere environments for warfighter and civilian health. The contract also supports the development of a solution to identify *Pathogen X*, in which an unknown pathogen must be characterized quickly. GeneCapture's point of care solution will identify which viral family is present in the sample within an hour so that rapid countermeasures can be taken.

The Company's mission is to develop rapid portable solutions for infection detection and antimicrobial susceptibility testing to quickly identify medicines to address the growing threats to civilians and the Warfighter from pathogens that cause disease. Current methods require specialized lab equipment and take several days.

GeneCapture's CAPTURE Platform™ delivers molecular pathogen identification in about an hour and antimicrobial susceptibility test results in another 1-2 hours, all in portable devices that can operate in remote areas without the need for refrigeration or other cold chain logistics. The novel technologies utilize 'Direct RNA Hybridization' to identify pathogens, and a custom flow cytometry method to measure colony growth.

GeneCapture's headquarters is on the campus of HudsonAlpha Institute for Biotechnology, a leading center for genomics research in human health and agricultural science.

###

GeneCapture Inc., a Huntsville, Alabama company has developed a portable rapid diagnostic platform for the identification and antimicrobial susceptibility of infection-causing pathogens. The Company's mission is to bring infection detection out of the lab and directly to the patient at the point of care, even in austere environments. GeneCapture's proprietary technology has the potential to transform identification and treatment of infectious disease – either on the battlefield, at the border, in rural communities or in hospital settings. Learn more about GeneCapture at www.genecapture.com or contact the company at info@genecapture.com.

HudsonAlpha Institute for Biotechnology is a nonprofit institute dedicated to developing and applying scientific advances to health, agriculture, learning, and commercialization. The state-of-the-art facilities co-locate nonprofit scientific researchers with entrepreneurs and educators. HudsonAlpha has become a national and international leader in genetics and genomics research and biotech education and fosters more than 45 diverse biotech companies on campus. hudsonalpha.org.